Capsules
Abstract
A method of making core-shell capsules containing a water-immiscible liquid, comprising the steps of (a) dispersing into the water-immiscible liquid a crosslinking agent that is inactive under the conditions of the dispersion; (b) emulsifying the resulting dispersion into an aqueous solution of a crosslinkable hydrocolloid; and (c) activating the crosslinking agent to cause the hydrocolloid to crosslink at the dispersion/solution interface. The method is simple and provides capsules that can be cold-loaded. The capsule material may be made of vegetable-derived materials.
Term
0.9 yearsleft in the term
Expires 31 August 2027.
- Priority
- Filed
- Granted
- Today
- Expires
5 claims: 1 independent, 4 dependent
- 1A method of making core-shell capsules containing a water-immiscible liquid, comprising the steps of (a) dispersing into the water-immiscible liquid a crosslinking agent that is inactive under the conditions of the dispersion;(b) emulsifying the resulting dispersion into an aqueous solution of a crosslinkable hydrocolloid;and (c) activating the crosslinking agent to cause the hydrocolloid to crosslink at the dispersion/solution interface.
24 paragraphs, as filed
0001This process relates to a method of preparing microcapsules, and more particularly to those utilising non-animal-derived hydrocolloids as wall material.
0002Hydrocolloids, colloidal suspensions of materials in water, are desirable materials for preparation of microcapsules, as they are readily and cheaply available from natural sources, both animal and vegetable. Typical examples are gelatine derived from various animals, and plant-derived gums, such as gellan gum. Some of these materials can be crosslinked, for example, by exposure to calcium or magnesium ions
0003In "<nplcit id="ncit0001" npl-type="s"><text>Production of alginate beads by emulsification/internal gelation. I. Methodology", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER-VERLAG, BE, vol. 38, 1992 , pages 39-45</text></nplcit>, Poncelet e.a. give a method for the production of alginate microspheres, i.e. homogeneous microparticles, dispersed in Canola oil. Said method comprises the steps of (a) dispersing a sodium alginate - calcium citrate mixture into Canola oil and (b) adding glacial acetic acid to the dispersion.
0004Previously, the formation of capsules has been achieved by coacervation, in which a shell is caused to form on dispersed core particles. This process has been used for many years, but it can be complex and difficult, often requiring very precise control of temperature and pH. It also uses animal derived materials (porcine, bovine, or piscine gelatine). This can be limiting, in that, in the case of flavors, many consumers do not wish to consume animal-derived products, either as a conscious vegetarian choice or in a desire to avoid animal-carried diseases, such as BSE ("mad cow disease").
0005It has now been found that it is possible to prepare core-shell capsules by a simple method that avoids the complexities of known methods. There is therefore provides a method of making core-shell capsules containing a water-immiscible liquid, comprising the steps of <ol id="ol0001" compact="compact"><li>(a) dispersing into the water-immiscible liquid a crosslinking agent that is inactive under the conditions of the dispersion;</li><li>(b) emulsifying the resulting dispersion into an aqueous solution of a crosslinkable hydrocolloid; and</li><li>(c) activating the crosslinking agent to cause the hydrocolloid to crosslink at the dispersion/solution interface.</li></ol>
0006The liquid to be encapsulated may be any suitable, desired water-immiscible liquid. It is typically a flavor oil, but it may also be any liquid that is not appreciably soluble in water and whose encapsulation is desired, for example a pharmaceutical. Non-limiting examples of flavor oils include amyl octanoate, benzyl cinnamate, decyl acetate, geranyl isovalerate, limonene, methyl salicylate, nootkatone, octyl butyrate, 2-pentylthiophene, phenylethyl isothiocyanate, delta-tetradecalactone, 2,2'-thiodimethylenedifuran, trithioacetone, and vanillin isobutyrate
0007The liquid may be used alone, or it may include a suitable water-immiscible solvent. The use of such solvents is already widely known and the skilled person will have no difficulty selecting a suitable solvent or solvent blend for any given application. One particularly desired solvent is MCT, medium chain triglycerides, which are readily-available commercial materials. These are essentially triesters of fatty acids with glycerol, and are low viscosity, low odor oils, which are stable to oxidation. A mixture of such liquids may be used, either separate in individual capsules or blended within the capsules. In addition, the liquid may be a solution of solid or gaseous material.
0008The hydrocolloid used in this invention may be any hydrocolloid suitable for use in encapsulation and able to be used in conjunction with the crosslinking agent, which will be described later in this description. Suitable hydrocolloids are generally derived from vegetable sources and they include (but are not limited to) food-grade alginate salts, pectin, curdlan gum and gellan gum. The potassium, sodium and ammonium alginates are all food-grade materials, sodium alginate being the most commonly encountered.
0009The crosslinking agent for use in this invention must be one that can be dissolved or dispersed into the encapsulated phase, that is inactive under the conditions of its dispersion or solution, and that can then be activated to crosslink the dissolved hydrocolloid in the continuous aqueous phase. Depending on the nature of the crosslinking agent, activation may be by any convenient means, such as temperature or pH change, irradiation or addition of an activating agent. In a typical example, the crosslinking agent may be calcium or magnesium ions. In such a case, calcium carbonate may be dispersed into the liquid to be encapsulated and the liquid in turn emulsified into an aqueous hydrocolloid solution, in which the hydrocolloid is crosslinkable by exposure to Ca<sup>++</sup> ions. At neutral pH, the calcium carbonate is water-insoluble. However, if the pH of the aqueous solution is made acidic, the calcium carbonate becomes more soluble and releases Ca<sup>++</sup> ions, which then cause crosslinking of the hydrocolloid at the droplet/aqueous solution interface to form a shell.
0010The process of the invention may be carried out easily in readily-available equipment.
0011The capsules may be made as capsules already loaded with the desired liquid to be encapsulated. Alternatively, they may be made as "blank" capsules and loaded with liquid when desired by any of the known methods of the art. Typical methods include those described in <patcit id="pcit0001" dnum="US6045835A"><text>US Patent 6,045,835</text></patcit>.
0012The capsules so prepared may be used in any of the wide range of applications in which an encapsulated material is desirable. Non-limiting examples include foodstuffs of all kinds, such as ice cream and water ice, soups, broths, and stews, noodles, pastas, and rice, meats and cheeses, spices and spice blends, and fried foods; beverages of all kinds, such as brewed teas, carbonated beverages, alcoholic beverages, energy drinks, dairy products, and juices; confections, such as gums, chocolates and candies of all kinds; baked goods of all kinds, such as cakes, cookies and biscuits; medicinal preparations in solid, liquid or spray form, toothpastes, toothgels and tooth powders; mouthwashes; cosmetic preparations in the form of creams, lotions and sprays;
0013Applications may comprise an application base and loaded capsules prepared as hereinabove described. By "application base" is meant a composition comprising all the other usual necessary ingredients that, in addition to the capsules, are needed to make up applications for use or consumption. The applications may contain all the standard ingredients that are required for the application to carry out its desired purpose, all being used in art-recognised quantities. Because of the many purposes to which applications according to this invention can be put, there are a great many of these and the list that follows is only a small sample, but the skilled person will readily be able to formulate any desired application using only the ordinary skill of the art. Typical examples include; pigments, coloring matters and dyestuffs; surfactants and emulsifiers; solvents and cosolvents; thickening agents and viscosity modifiers; fillers and extenders; antioxidants and preservatives; UV absorbers; foaming agents; defoaming agents; and the like.
0014The invention is now further described with reference to the following non-limiting examples.
Example 1
Preparation of "blank" capsules
0015To a 1 liter beaker containing 495 g of distilled water, 5 g of sodium alginate (Keltone<sup>™</sup> LV) was added. This mixture was stirred at moderate speed until the alginate was completely dissolved. To a 250 ml beaker containing 43.2 g of MCT, 2.8 g of finely-powdered CaCO<sub>3</sub> was added. This mixture was stirred at moderate speed to uniformly disperse the CaCO<sub>3</sub>. This dispersion was added to the alginate solution, the pH of which was neutral, while stirring at moderate speed. When the desired droplet size of 100 - 500 microns was reached, 50% citric acid was added to lower the pH to 4.5. After several minutes, the batch became viscous and 500 g of distilled water was added to dilute the system. The batch was allowed to stir at moderate speed for several hours. Over this time period, the size of the capsules walls grew significantly. The following day, the capsules were concentrated and dried using conventional methods.
Example 2
Preparation of flavor-containing capsules
0016To a 2 liter beaker containing 995 g of distilled water, 5 g of sodium alginate (Keltone<sup>™</sup> LV) was added. This mixture was stirred at high speed until the sodium alginate was completely dissolved. To a 250 ml beaker containing 43.2 g d-limonene, 2.8 g of finely-powdered CaCO<sub>3</sub> was added. This mixture was stirred at moderate speed to uniformly disperse the CaCO<sub>3</sub>. This dispersion was added to the alginate solution, the pH of which was neutral, while stirring at moderate speed. When the desired droplet size of 500-1000 microns was achieved, 50% citric acid solution was added to lower the pH to 5. The pH of the batch was monitored while stirring at moderate speed. Over time, the pH rose and additional 50% citric acid solution was added to maintain the pH around 5. This was continued until the pH remained unchanged. The batch was allowed to stir overnight. Agitation was then stopped and the capsules were washed with fresh water and concentrated. The concentrated capsule slurry was then added to a 1 liter beaker containing 500 grams of a 2% CaCl<sub>2</sub> solution to finalize crosslinking and strengthen the walls. The capsules were stirred in this solution for several hours. The capsules were again washed with water to remove any residual CaCl<sub>2</sub> and stored in water.
Example 3
Cold loading of blank capsules
001714.6 g of dried capsules from example 1 and 1.4 g of water were mixed thoroughly to uniformly distribute the water. The capsule walls were allowed to for 15 minutes. 4 g of acetophenone was added to the hydrated capsules and the mixture mixed thoroughly and then allowed to stand overnight.
0018The release of the flavor into water was determined by dissolution of the loaded capsules into 500 ml 30° C water. The capsules were found to release about 50% of the encapsulated flavor in 10 minutes and 75% in 30 minutes.
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| EP0856355A | Cites | European Patent Office (EPO) |
| US4822534A | Cites | United States of America |
| PONCELET D ET AL: "Production of alginate beads by emulsification/internal gelation. I. Methodology" APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER-VERLAG, BE, vol. 38, 1992, pages 39-45, XP009090637 ISSN: 1432-0614 | Non-patent | – |
| PONCELET, D.: "Production of Alginate Beads by Emulsification/Internal Gelation" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 944, no. 1, 2001, pages 74-82, XP002464386 | Non-patent | – |
| ESQUISABEL A ET AL: "PRODUCTION OF BCG ALGINATE-PLL MICROCAPSULES BY EMULSIFICATION/INTERNAL GELATION" JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS, BASINGSTOKE, GB, vol. 14, no. 5, September 1997 (1997-09), pages 627-638, XP000659518 ISSN: 0265-2048 | Non-patent | – |
15 members in 9 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 844049P | United States of America | – | |
| 84404906 | United States of America | P | |
| 2007000432 | Switzerland | W |
Members15
| Document | Office | Kind | |
|---|---|---|---|
| WO2008031241A1 | World Intellectual Property Organization (WIPO) | A1 | |
| EP2071919A1 | European Patent Office (EPO) | A1 | |
| CN101516492A | China | A | |
| US2010003521A1 | United States of America | A1 | |
| JP2010502439A | Japan | A | |
| EP2071919B1This record | European Patent Office (EPO) | B1 | |
| AT484337T | Austria | T | |
| ATE484337T1 | Austria | T1 | |
| DE602007009855D1 | Germany | D1 | |
| CN101516492B | China | B | |
| US8465835B2 | United States of America | B2 | |
| BRPI0716797A2 | Brazil | A2 | |
| JP5607361B2 | Japan | B2 | |
| IN1381CHN2009A | India | A | |
| BRPI0716797B1 | Brazil | B1 |
67 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| New agentNV | NV | CH | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Epo decision maintaining patent unamended now finalR100 | R100 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Opposition rejectedOpposition27O | 27O | EP | |
| Opposition rejectedOppositionORIGINAL CODE: 0009273PLBN | PLBN | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: OPPOSITION REJECTEDSTAA | STAA | EP | |
| Communication despatched that opposition was rejectedOppositionORIGINAL CODE: EPIDOSNREJ1PLCK | PLCK | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| New agentNV | NV | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Opposition filed against patentOppositionR026 | R026 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lt: invalidation of european patent or patent extensionLTIE | LTIE | EP | |
| Translation filed for an european patent granted for nl, confirming art. 52 par. 1 or 6 of the patents act 1995GrantedT3 | T3 | NL | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 2071919
- Application
- 77851194
Titles3
- German
- KAPSELN
- English
- CAPSULES
- French
- CAPSULES
Classification
- CPC, 4
- B01J13/14
- Y10T428/2985
- Y10T428/2984
- Y10T428/2982
- IPC, 2
- B01J13 14
- B32B1 00
Designated states32
- Contracting states, 32
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
- Monaco
- Malta
and 8 moreShow fewer
- Netherlands (Kingdom of the)
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye